R&D as Competitive Advantage
Quick definition: Fisher's framework for assessing whether companies maintain sufficient research and development investments to sustain competitive advantages and generate continuous streams of new or improved products that drive long-term growth.
Key Takeaways
- Adequate R&D spending is prerequisite for growth company investment, as it signals management's commitment to maintaining competitive positioning over decades rather than maximizing current earnings
- The quality and direction of R&D spending matters more than absolute levels; research focused on core competitive advantages and genuine market needs creates more value than broadly scattered innovation
- Companies that cut R&D during downturns often signal management's prioritization of near-term earnings over long-term positioning, a warning sign of deteriorating leadership quality
- Effective R&D requires culture that tolerates intelligent failure and encourages experimentation, which financial statements cannot capture but scuttlebutt research can reveal
- Leading companies often spend R&D at levels that temporarily depress earnings but position them to capture disproportionate share of future growth
The Sustainability Paradox
Philip Fisher recognized a fundamental paradox in growth investing. A company demonstrating exceptional earnings growth might be in the process of destroying its competitive advantages. If that company was achieving earnings growth by cutting research investment or deferring capital expenditure, the growth was temporary. Within a few years, lack of new products or process improvements would become apparent. Competitors' newer products would win market share. Manufacturing efficiency would lag. Market position would erode.
Conversely, a company reporting solid but unspectacular earnings growth might be in the process of building durable competitive advantages. If that company was investing heavily in research, developing promising new products, and improving processes, it was positioning itself for long-term dominance. The near-term earnings would be temporarily suppressed by investment, but the long-term trajectory would be exceptional.
This paradox meant that evaluating R&D required looking beyond current earnings to understand the direction of competitive positioning. The investor had to ask: Will this company be stronger or weaker competitively five years from now? If management was cutting investment to boost current earnings, the company would be weaker. If management was maintaining robust investment despite pressuring near-term results, the company was likely to be stronger.
Assessing Research Adequacy
Fisher's approach to evaluating R&D wasn't mechanical. A company couldn't simply be judged based on R&D as a percentage of revenue, because appropriate levels varied by industry. A pharmaceutical company might need to spend 15–20 percent of revenue on research because of the regulatory requirements of drug development and the high failure rate of research projects. A consumer goods company might appropriate adequately maintain market position with 3–5 percent. A capital equipment manufacturer might invest 5–8 percent.
The investor needed to understand the industry context and then assess whether a particular company was investing adequately relative to competitive threats and opportunities. This required scuttlebutt research—conversations with engineers about whether the company attracted top talent, with customers about the pace of product innovation, with competitors about the relative quality of new offerings.
Were the company's research facilities modern and well-equipped? Was the company hiring top scientists and engineers, or was it struggling to attract talent? Were new products emerging regularly, or had the pipeline slowed? Were customers choosing the company's latest offerings over previous versions, suggesting product improvement, or were they postponing purchases awaiting newer versions? Were competitors' R&D efforts showing signs of producing superior products? Had the company's research leadership been stable, or had talented executives been leaving for opportunities elsewhere?
These qualitative observations were often more revealing than R&D spending percentages. A company spending generously on research but producing mediocre results was failing to convert investment into advantage. A company with exceptionally talented research organization producing consistent stream of valuable innovations was efficiently deploying capital.
Research Direction and Focus
Fisher emphasized that the strategic direction of research was as important as total spending. A company might spend substantially on research, but if research was scattered across numerous unrelated projects with minimal connection to core competitive strengths, it wasn't an effective competitive investment. Research that diluted focus and stretched organizational capabilities across too many directions often generated mediocre results.
The strongest companies typically focused research on core competitive advantages and genuine market needs. If a company had technological leadership in materials science, research directed at improving material properties and finding new applications represented focused investment. If that same company tried to leverage its materials expertise into pharmaceuticals or software despite lacking genuine edge in those areas, research spending became corporate overhead rather than competitive advantage.
This distinction explained why some companies generated exceptional returns from modest R&D investment while others struggled despite generous research budgets. Focused research amplified existing strengths. Scattered research dissipated organizational capability without creating defensible position.
Organizational Culture and Experimentation
The quality of a company's research organization extended beyond funding and focus to include culture. Did the company tolerate intelligent failure, recognizing that research inherently involves trying ideas that won't work? Or did the company punish failure in ways that discouraged risk-taking and encouraged researchers to focus only on ideas with near-certain success? Did the company allow researchers to spend some portion of time on exploratory projects not directly tied to current products, or was every hour accounted for in terms of immediate commercial application?
These cultural questions couldn't be answered from financial statements. They required genuine conversations with engineers, either currently employed or formerly employed. An engineer at a great research company often described excitement about projects, confidence in organizational support for experimentation, and sense that failure was educational. An engineer at a mediocre research company often described frustration with excessive process, concern about failure impacting career, and sense that genuine innovation was discouraged in favor of incremental improvements to existing products.
The companies generating exceptional long-term returns often had research organizations where talented scientists and engineers felt liberated to pursue ambitious ideas. Companies that treated research as a cost center under tight budget control rarely generated breakthrough innovations. Yet the paradox was that liberating research organizations was expensive and temporarily depressed earnings. This created the opportunity for disciplined investors to recognize emerging competitive advantage before the market priced it in.
Signaling Through Investment Cycles
How a company managed R&D investment through economic cycles was often the clearest signal of management integrity and long-term orientation. When earnings faced pressure from recession or competitive intensity, what did management prioritize?
Bad managers cut R&D aggressively, knowing the impact on future competitive position wouldn't be apparent for years. Near-term earnings benefited. Career consequences for the manager were immediate, while competitive consequences were future. This made it an attractive decision for self-interested managers. But companies that cut R&D during downturns often emerged from recession in weaker competitive positions, struggling to regain share as recovery occurred.
Good managers maintained R&D investment during downturns despite earnings pressure. They recognized that recessions were opportunities to strengthen competitive positioning while competitors were cutting corners. Companies that maintained R&D investment through downturns often emerged from recession in stronger competitive positions, having developed new products or improved processes while competitors had deferred innovation.
This behavior was visible in historical performance. The investor could examine how a company managed R&D during previous recessions. Had the company been willing to accept lower earnings to maintain investment? Or had it cut aggressively to protect near-term results? This historical pattern predicted management's likely behavior in future downturns.